-
PerkinElmer to acquire Abingdon-based Oxford Immunotec
Under the terms of the Acquisition, Oxford Immunotec shareholders will be entitled to receive $22.00 in cash for each outstanding ordinary share.
-
Ex-Centrica and BP boss Iain Conn joins Oxford Flow board
The energy industry veteran Conn brings 35 years of experience to the post, including 29 years with BP, 10 of which were on BP’s Board, latterly as CEO Downstream.
-
Oxford Instruments delivers Proteox to Oxford Quantum Circuits
Oxford Quantum Circuits (OQC) is taking delivery of Oxford Instruments’ next-generation Cryofree® refrigerator, Proteox.
-
Oxbotica raises $47m to deploy autonomy software platform around the world
The funding will accelerate Oxbotica’s commercial deployment of its world-class autonomy software platform across multiple industries and key markets.
-
Custodian REIT acquires Willow Court on Minns Business Park
The 22,545 sq ft office building is located one mile west of Oxford city centre, and adjacent to the A34, which connects the M4 and M40.
-
Abingdon-based Scientific Magnetics to merge with Australian Magnetica
The merger completion is subject only to Magnetica’s shareholder approval at an upcoming General Meeting on 29 January.
-
Owen Mumford chosen as sole supplier for safety pen needles in Wales
Ateria® SafeControl® safety pen needles will now be used in all NHS Wales hospital environments, as well as by community nurses who also have access to the new procurement framework.
-
Grundon strengthens Board of Directors with two new appointments
Simon Arnold has been appointed Finance Director, whilst Jonathan Harris takes over as Technical Director of Wallingford-based Grundon Waste Management.
-
Oxford City Council set to pedestrianise North Parade
The pedestrianisation, which has been supported by Oxfordshire County Council and local councillors, was requested by the North Parade Residents and Traders Association.
-
Biotech start-up DJS Antibodies raises £6m in seed funding
The biotech start-up company based in Upper Heyford will use the funds to accelerate the development of its novel antibody therapeutics for inflammatory disease.
